Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

Yeona Cho, Sangjoon Park, Hwa Kyung Byun, Chang Geol Lee, Jaeho Cho, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho, Sinae Kim, Juyoung Park, Hong In Yoon

Research output: Contribution to journalArticle

Abstract

Purpose: The interest in combining radiation therapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving immunotherapy for non-small cell lung cancer (NSCLC), and the factors associated with treatment-related lymphopenia, with particular emphasis on RT. Methods and Methods: In this retrospective single institution study, 268 patients with advanced NSCLC received immunotherapy, of whom 146 received RT. Lymphopenia was defined as an absolute lymphocyte count <1000 cells/mm.3 Patients were divided into 2 groups depending on the presence of peri-immunotherapy lymphopenia at the start of immunotherapy or during immunotherapy. Results: At median 6.4 months of follow-up, patients with peri-immunotherapy lymphopenia (n = 146; 54.5%) showed significantly poorer progression-free survival (PFS) (median PFS: 2.2 vs 5.9 months, P <.001) and overall survival (OS) (median OS: 5.7 vs 12.1 months, P <.001). On multivariate analysis, peri-immunotherapy lymphopenia remained a significant prognostic factor for both PFS and OS. RT significantly increased peri-immunotherapy lymphopenia with an odds ratio (OR) of 1.91 (P =.025). Factors associated with the development of RT-associated lymphopenia included multiple courses (OR, 3.78; P <.001), multiple irradiated sites (OR, 4.77; P =.018), and higher dose (≥50 Gy) (OR, 3.75; P =.004). Conversely, stereotactic body RT/radiosurgery reduced the risk (OR 0.21; P =.002). Conclusions: Lymphopenia was indicative of poor prognosis in NSCLC patients receiving immunotherapy and was significantly associated with more intensive RT. Choosing appropriate RT regimens and techniques may be essential in reducing lymphopenia. Promising results are expected in the era of precision RT.

Original languageEnglish
JournalInternational Journal of Radiation Oncology Biology Physics
DOIs
Publication statusAccepted/In press - 2019 Jan 1

Fingerprint

Lymphopenia
Non-Small Cell Lung Carcinoma
Immunotherapy
lungs
radiation therapy
cancer
Radiotherapy
Odds Ratio
progressions
Disease-Free Survival
Therapeutics
Survival
prognosis
lymphocytes
Radiosurgery
Lymphocyte Count
Multivariate Analysis
dosage

All Science Journal Classification (ASJC) codes

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Cho, Yeona ; Park, Sangjoon ; Byun, Hwa Kyung ; Lee, Chang Geol ; Cho, Jaeho ; Hong, Min Hee ; Kim, Hye Ryun ; Cho, Byoung Chul ; Kim, Sinae ; Park, Juyoung ; Yoon, Hong In. / Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. In: International Journal of Radiation Oncology Biology Physics. 2019.
@article{7d79fa5221a94999b66a9d7a962800e7,
title = "Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer",
abstract = "Purpose: The interest in combining radiation therapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving immunotherapy for non-small cell lung cancer (NSCLC), and the factors associated with treatment-related lymphopenia, with particular emphasis on RT. Methods and Methods: In this retrospective single institution study, 268 patients with advanced NSCLC received immunotherapy, of whom 146 received RT. Lymphopenia was defined as an absolute lymphocyte count <1000 cells/mm.3 Patients were divided into 2 groups depending on the presence of peri-immunotherapy lymphopenia at the start of immunotherapy or during immunotherapy. Results: At median 6.4 months of follow-up, patients with peri-immunotherapy lymphopenia (n = 146; 54.5{\%}) showed significantly poorer progression-free survival (PFS) (median PFS: 2.2 vs 5.9 months, P <.001) and overall survival (OS) (median OS: 5.7 vs 12.1 months, P <.001). On multivariate analysis, peri-immunotherapy lymphopenia remained a significant prognostic factor for both PFS and OS. RT significantly increased peri-immunotherapy lymphopenia with an odds ratio (OR) of 1.91 (P =.025). Factors associated with the development of RT-associated lymphopenia included multiple courses (OR, 3.78; P <.001), multiple irradiated sites (OR, 4.77; P =.018), and higher dose (≥50 Gy) (OR, 3.75; P =.004). Conversely, stereotactic body RT/radiosurgery reduced the risk (OR 0.21; P =.002). Conclusions: Lymphopenia was indicative of poor prognosis in NSCLC patients receiving immunotherapy and was significantly associated with more intensive RT. Choosing appropriate RT regimens and techniques may be essential in reducing lymphopenia. Promising results are expected in the era of precision RT.",
author = "Yeona Cho and Sangjoon Park and Byun, {Hwa Kyung} and Lee, {Chang Geol} and Jaeho Cho and Hong, {Min Hee} and Kim, {Hye Ryun} and Cho, {Byoung Chul} and Sinae Kim and Juyoung Park and Yoon, {Hong In}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.ijrobp.2019.08.047",
language = "English",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",

}

Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. / Cho, Yeona; Park, Sangjoon; Byun, Hwa Kyung; Lee, Chang Geol; Cho, Jaeho; Hong, Min Hee; Kim, Hye Ryun; Cho, Byoung Chul; Kim, Sinae; Park, Juyoung; Yoon, Hong In.

In: International Journal of Radiation Oncology Biology Physics, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer

AU - Cho, Yeona

AU - Park, Sangjoon

AU - Byun, Hwa Kyung

AU - Lee, Chang Geol

AU - Cho, Jaeho

AU - Hong, Min Hee

AU - Kim, Hye Ryun

AU - Cho, Byoung Chul

AU - Kim, Sinae

AU - Park, Juyoung

AU - Yoon, Hong In

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Purpose: The interest in combining radiation therapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving immunotherapy for non-small cell lung cancer (NSCLC), and the factors associated with treatment-related lymphopenia, with particular emphasis on RT. Methods and Methods: In this retrospective single institution study, 268 patients with advanced NSCLC received immunotherapy, of whom 146 received RT. Lymphopenia was defined as an absolute lymphocyte count <1000 cells/mm.3 Patients were divided into 2 groups depending on the presence of peri-immunotherapy lymphopenia at the start of immunotherapy or during immunotherapy. Results: At median 6.4 months of follow-up, patients with peri-immunotherapy lymphopenia (n = 146; 54.5%) showed significantly poorer progression-free survival (PFS) (median PFS: 2.2 vs 5.9 months, P <.001) and overall survival (OS) (median OS: 5.7 vs 12.1 months, P <.001). On multivariate analysis, peri-immunotherapy lymphopenia remained a significant prognostic factor for both PFS and OS. RT significantly increased peri-immunotherapy lymphopenia with an odds ratio (OR) of 1.91 (P =.025). Factors associated with the development of RT-associated lymphopenia included multiple courses (OR, 3.78; P <.001), multiple irradiated sites (OR, 4.77; P =.018), and higher dose (≥50 Gy) (OR, 3.75; P =.004). Conversely, stereotactic body RT/radiosurgery reduced the risk (OR 0.21; P =.002). Conclusions: Lymphopenia was indicative of poor prognosis in NSCLC patients receiving immunotherapy and was significantly associated with more intensive RT. Choosing appropriate RT regimens and techniques may be essential in reducing lymphopenia. Promising results are expected in the era of precision RT.

AB - Purpose: The interest in combining radiation therapy (RT) with immunotherapy is increasing. We investigated the significance of lymphopenia in patients receiving immunotherapy for non-small cell lung cancer (NSCLC), and the factors associated with treatment-related lymphopenia, with particular emphasis on RT. Methods and Methods: In this retrospective single institution study, 268 patients with advanced NSCLC received immunotherapy, of whom 146 received RT. Lymphopenia was defined as an absolute lymphocyte count <1000 cells/mm.3 Patients were divided into 2 groups depending on the presence of peri-immunotherapy lymphopenia at the start of immunotherapy or during immunotherapy. Results: At median 6.4 months of follow-up, patients with peri-immunotherapy lymphopenia (n = 146; 54.5%) showed significantly poorer progression-free survival (PFS) (median PFS: 2.2 vs 5.9 months, P <.001) and overall survival (OS) (median OS: 5.7 vs 12.1 months, P <.001). On multivariate analysis, peri-immunotherapy lymphopenia remained a significant prognostic factor for both PFS and OS. RT significantly increased peri-immunotherapy lymphopenia with an odds ratio (OR) of 1.91 (P =.025). Factors associated with the development of RT-associated lymphopenia included multiple courses (OR, 3.78; P <.001), multiple irradiated sites (OR, 4.77; P =.018), and higher dose (≥50 Gy) (OR, 3.75; P =.004). Conversely, stereotactic body RT/radiosurgery reduced the risk (OR 0.21; P =.002). Conclusions: Lymphopenia was indicative of poor prognosis in NSCLC patients receiving immunotherapy and was significantly associated with more intensive RT. Choosing appropriate RT regimens and techniques may be essential in reducing lymphopenia. Promising results are expected in the era of precision RT.

UR - http://www.scopus.com/inward/record.url?scp=85073003946&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073003946&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2019.08.047

DO - 10.1016/j.ijrobp.2019.08.047

M3 - Article

C2 - 31476418

AN - SCOPUS:85073003946

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

ER -